Cancer Research Cancer Epigenetics  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Published online first on February 10, 2009
[Cancer Research, 10.1158/0008-5472.CAN-08-3030]
This Article
Right arrow Full Text (Online First [PDF])
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-08-3030v1
69/4/1324    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nasarre, P.
Right arrow Articles by Augustin, H. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nasarre, P.
Right arrow Articles by Augustin, H. G.

Cell, Tumor, and Stem Cell Biology

Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth

Patrick Nasarre 1, Markus Thomas 2, Karoline Kruse 2, Iris Helfrich 2, Vivien Wolter 2, Carleen Deppermann 2, Dirk Schadendorf 3, Gavin Thurston 4, Ulrike Fiedler 1, Hellmut G. Augustin 1, 2*

1Department of Vascular Biology and Angiogenesis Research, Tumor Biology Center, Freiburg, Germany; 2Joint Research Division Vascular Biology, Medical Faculty Mannheim (CBTM), University of Heidelberg, and German Cancer Research Center (DKFZ-ZMBH Alliance); 3Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany; and 4Regeneron Pharmaceuticals, Tarrytown, New York

* To whom correspondence should be addressed. E-mail: augustin{at}angiogenese.de.


   Abstract

The angiopoietin/Tie2 system has been identified as the second vascular-specific receptor tyrosine kinase system controlling vessel assembly, maturation, and quiescence. Angiopoietin-2 (Ang-2) is prominently up-regulated in the host-derived vasculature of most tumors, making it an attractive candidate for antiangiogenic intervention. Yet, the net outcome of Ang-2 functions on tumor angiogenesis is believed to be contextual depending on the local cytokine milieu. Correspondingly, Ang-2 manipulatory therapies have been shown to exert protumorigenic as well as antitumorigenic effects. To clarify the role of Ang-2 for angiogenesis and tumor growth in a definite genetic experimental setting, the present study was aimed at comparatively studying the growth of different tumors in wild-type and Ang-2–deficient mice. Lewis lung carcinomas, MT-ret melanomas, and B16F10 melanomas all grew slower in Ang-2–deficient mice. Yet, tumor growth in wild-type and Ang-2–deficient mice dissociated during early stages of tumor development, whereas tumor growth rates during later stages of primary tumor progression were similar. Analysis of the intratumoral vascular architecture revealed no major differences in microvessel density and perfusion characteristics. However, diameters of intratumoral microvessels were smaller in tumors grown in Ang-2–deficient mice, and the vasculature had an altered pattern of pericyte recruitment and maturation. Ang-2–deficient tumor vessels had higher pericyte coverage indices. Recruited pericytes were desmin and NG2 positive and predominately {alpha}-smooth muscle actin negative, indicative of a more mature pericyte phenotype. Collectively, the experiments define the role of Ang-2 during tumor angiogenesis and establish a better rationale for combination therapies involving Ang-2 manipulatory therapies. [Cancer Res 2009;69(4):1324–33]

Key Words: angiogenesis, tumor progression, Angiopoietin-2, Tie2, endothelial cell




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
B. L. Falcon, H. Hashizume, P. Koumoutsakos, J. Chou, J. V. Bready, A. Coxon, J. D. Oliner, and D. M. McDonald
Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels
Am. J. Pathol., November 1, 2009; 175(5): 2159 - 2170.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Ahmad, S. Ahmad, L. Glover, S. M. Miller, J. M. Shannon, X. Guo, W. A. Franklin, J. P. Bridges, J. B. Schaack, S. P. Colgan, et al.
Adenosine A2A receptor is a unique angiogenic target of HIF-2{alpha} in pulmonary endothelial cells
PNAS, June 30, 2009; 106(26): 10684 - 10689.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Y. Cheranov, D. Wang, V. Kundumani-Sridharan, M. Karpurapu, Q. Zhang, K. R. Chava, and G. N. Rao
The 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires Janus kinase 2-signal transducer and activator of transcription-5B-dependent expression of interleukin-8
Blood, June 4, 2009; 113(23): 6023 - 6033.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.